Astrid Fahrleitner‐Pammer

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi et al. · The Lancet Diabetes & Endocrinology · 2017 · 961 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

David L. Kendler, Fernando Marín, Cristiano A. F. Zerbini et al. · The Lancet · 2017 · 581 citations · Full text

Medicine, Endocrinology, Gynecology +15

Women Underrepresented on Editorial Boards of 60 Major Medical Journals

Karin Amrein, Andrea Langmann, Astrid Fahrleitner‐Pammer et al. · Gender Medicine · 2011 · 319 citations

Medicine, Biomedical Sciences, Gynecology +9

Sclerostin and Its Association with Physical Activity, Age, Gender, Body Composition, and Bone Mineral Content in Healthy Adults

Karin Amrein, Steven Amrein, Camilla Drexler et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 283 citations · Full text

Medicine, Endocrinology, Bone Metabolism +15

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

Ian R. Reid, Paul D. Miller, Jacques P. Brown et al. · Journal of Bone and Mineral Research · 2010 · 252 citations · Full text

Medicine, Orthopaedic Surgery, Bone Augmentation +16